Lack of Association Between Low Density Lipoprotein Particle Size and On-Treatment Platelet Reactivity in Patients With Coronary Artery Disease

Do-Yoon Kang, MD,1 Han-Mo Yang, MD,1 Kyung Woo Park, MD,1 So-Ryoung Lee, MD,1 Min-Ho Lee, MD,1 Dong-Won Lee, MD,1 Hae-Young Lee, MD,1 Hyun-Jae Kang, MD,1 Bon-Kwon Koo, MD,1 In-Ho Chae, MD,2 Dong-Ju Choi, MD,2 Hyo-Soo Kim, MD,1 and Cheol-Ho Kim, MD,2

1Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital, Seoul, Korea
2Department of Internal Medicine, Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam, Korea

Background and Objectives: Small dense low density lipoproteins (sd-LDL) are a risk factor for coronary artery disease and are known to stimulate platelet function in vitro. This study aimed to evaluate whether high proportion of sd-LDL is associated with high on-treatment platelet reactivity (HOPR).

Subjects and Methods: From January 2009 to March 2010, 439 subjects (mean age: 64.3 ± 9.7, Male : Female=306 : 133) were enrolled from the low density LIPOProtein-cholesterol Size measurement Registry with coronary artery disease, who had undergone elective percutaneous coronary intervention and measured both LDL particle size and on-treatment platelet reactivity (OPR). Mean LDL particle size was measured by gradient gel electrophoresis (Quantimetrix, Lipoprint™) and OPR by the VerifyNow™ system (aspirin and P2Y12).

Results: Between pattern A (large, buoyant LDL dominant) and B (sd-LDL dominant) population, there were no significant difference in OPR to aspirin (441.3 ± 71.9 vs. 434.07 ± 63.45 aspirin reaction units, p=0.351) or clopidogrel (237.9 ± 87.3 vs. 244.9 ± 80.7 P2Y12 reaction units, p=0.465). There was no difference in LDL particle size between patients with HOPR compared with non-HOPR patients (aspirin: 26.8±0.5 vs. 26.7±0.6 nm, p=0.078, clopidogrel: 26.7±0.6 vs. 26.8±0.5 nm, p=0.857). Pearson’s correlation coefficients between LDL particle size and platelet reactivity were not statistically significant (aspirin assay: r=0.080, p=0.098, P2Y12 assay: r=-0.027, p=0.568).

Conclusion: There was no significant association between LDL particle size and OPR in patients with coronary artery disease. (Korean Circ J 2012;42:551-557)

KEY WORDS: Lipoproteins; Low-density lipoprotein; Platelet Function Tests.

Introduction

High on-treatment platelet reactivity (HOPR) to antiplatelet therapy has been shown to be associated with atherothrombotic vascular complications after percutaneous coronary intervention (PCI).1-3 Small dense low density lipoproteins (sd-LDL) have become recognized as a potential risk factor of coronary and non-coronary forms of atherosclerosis.4-7 They penetrate the arterial wall more easily and have high binding affinity to arterial proteoglycan, resulting in subendothelial accumulation in the early stage of atherogenesis.8-10 Furthermore, sd-LDL particles may enhance thromboxane synthesis and promote platelet aggregation.11 If sd-LDL is...
associated with HOPR in patients, this may suggest therapeutic implication of a more intensive treatment of dyslipidemia. Thus, we aimed to examine the possible relationship between LDL particle size and on-treatment platelet reactivity (OPR) in patients receiving antiplatelet therapy.

**Subjects and Methods**

**Subjects**

The LOW density LIPOprotein-cholesterol Particle Size measurement study was a prospective registry that included patients with coronary artery disease who had undergone a lipid profile analysis and measurement of LDL particle size at Seoul National University Bundang Hospital. The inclusion criteria for the present analysis were patients who had undergone PCI and received dual antiplatelet therapy with aspirin and clopidogrel. From January 2009 through March 2010, a total of 434 consecutive patients were enrolled and all patients underwent platelet function testing. Patients with the following conditions were excluded from the study; on long-term (more than 2 weeks) statin therapy before lipid particle size measurement, with chronic renal failure, had severe hepatic failure, or had a cancer malignancy.

The diagnosis of diabetes mellitus was based on a history of treatment with either oral anti-diabetic agents or insulin or HbA1c ≥6.5%. Hypertension was defined as a history of treatment with anti-hypertensive agents or systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg. Body mass index was calculated as weight (kg)/height\(^2\) (m\(^2\)).

**Lipoprotein and low density lipoprotein particle size measurement**

Fasting blood samples were obtained by venipuncture on the day of the PCI. Serum was separated by centrifugation and biochemical measurements were conducted immediately. Serum glucose, total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), and triglyceride were measured enzymatically using the Hitachi 747 chemical analyzer (Hitachi, Tokyo, Japan).

Low density lipoprotein particle size was determined using a gel electrophoresis (Lipoprint™ System; Quantimetrix Corp., Redondo Beach, CA, USA) according to the manufacturer’s instructions. This method estimates LDL particle size by comparing their electrophoretic mobility using very low density lipoprotein as the starting point (Retention factor (R\(_i\))=0) and HDL as the end point (R\(_i\)=1). Because the R\(_i\) value obtained by this method correlated well with the peak LDL size obtained by ultracentrifugation, LDL peak particle sizes (PPS) could be derived from the work of Kazumi et al. \(^{18}\) PPS=(1.429-R\(_i\))×25, and the PPS values of the LDL-1 to LDL-7 bands were 27.7, 26.1, 24.5, 23.0, 21.8, 20.7 and 18.7 nm, respectively. \(^{14}\) The mean LDL particle diameter (in nm) was expressed as the weighted average of the PPS of all LDL subfractions as follows: \[\frac{\sum (\text{LDL} / \text{LDL}) \times \text{size}}{\text{LDL}}\]. LDL was the area of the LDL bands relative to LDL-C and size was the PPS of the LDL band. We categorized patients into pattern A (large, buoyant LDL dominant) and pattern B (small, dense LDL dominant) by mean LDL particle diameter and cutoff value was defined as the smallest quartile (26.5 nm). \(^{15}\) Mean particle diameter over 26.5 nm was defined as pattern A and diameter of ≤26.5 nm was defined as pattern B. The sd-LDL fraction (%) was measured as proportion of sd-LDL (sum of subtypes LDL3-LDL7) to the sum of LDL1-LDL7.

**Platelet function test**

The magnitude of OPR was quantified using the VerifyNow™ system (Accumetrics, Inc., San Diego, CA, USA). The VerifyNow™ system is a whole blood cartridge-based method to determine the magnitude of platelet agglutination induced by either arachidonic acid in the aspirin assay and adenosine diphosphate (ADP) and prostaglandin E\(_{2}\) in P2Y12 assay. \(^{16}\) Platelet reactivity was reported as aspirin reaction units (ARU) and P2Y12 reaction units (PRU) and higher reaction unit reflected higher OPR. HOPR was defined as OPR greater than 454 ARU\(^{17}\) or 264 PRU\(^{17}\) according to previous studies. OPR was measured on the morning after drug administration in chronic users and 12-24 hours after loading dose (300 mg for aspirin, and 300-600 mg of clopidogrel) for naïve patients.

**Statistical analysis**

Continuous variables were presented as either mean±SDs or median with interquartile ranges and categorical variables as numbers and percentages. A comparison of continuous variables was performed using the Student’s t-test or in case of non-normal distribution, Mann-Whitney U test when appropriate. Categorical variables were compared using chi-square test or Fisher’s test when appropriate. Pearson’s correlation coefficient was used to assess association between LDL particle size and OPR. Univariate and multivariate logistic regression analyses were performed to adjust for possible confounding effects of clinical characteristics and laboratory findings on the occurrence of HOPR.

Statistical Package for the Social Sciences Statistics (IBM Corporation, NY, USA) version 19.0 was used for all statistical analyses and \(p<0.05\) was considered statistically significant.

**Results**

**Population characteristics**

The clinical characteristics of the 434 patients included in the an-
Analysis were shown in Table 1 according to the pattern of LDL particle size. The mean LDL particle size of the patients was 26.74 ± 0.56 nm (median 26.8 nm, inter-quartile range 26.5-27.1 nm) included in this study. Patients with pattern B were less likely to have been treated with statins before admission {153 (46.8%) vs. 36 (33.6%), p=0.019}, leading to higher TC (146.13 ± 34.71 vs. 169.10 ± 35.31 mg/dL, p<0.001) and lower HDL (35.69 ± 10.06 vs. 31.15 ± 7.47 mg/dL, p<0.001) in these patients. Otherwise, there were no significant differences in clinical characteristics between pattern A and B. In addition, the mean ARU and PRU as well as the frequency of high on-aspirin platelet reactivity (HAPR, ARU>454) and high on-clopidogrel platelet reactivity (HCPR, PRU>264) were not different between the 2 groups. Statin medication before admission was the only significant predictor of pattern B on univariate and multivariate analyses.

### Relationship between mean low density lipoprotein particle size and platelet reactivity

There was no significant correlation between mean LDL particle size and ARU level (r=0.080, p=0.098). Similarly, PRU levels were not correlated with mean LDL particle size (r=-0.027, p=0.568) (Fig. 1). Also in non-acute coronary syndrome (ACS) patients, there were no significant correlations among mean LDL particle size and ARU (r=-0.015, p=0.826) or PRU (r=-0.125, p=0.076) levels.

### Clinical characteristics of patients with high on-aspirin platelet reactivity

Next, patients were grouped according to whether they had HAPR or HCPR. A total of 148 patients was identified as having HAPR (Table 2). Compared with the non-HAPR group, those in the HAPR group were older (63.5±9.3 vs. 65.8±10.5 years, p=0.023), had lower hemoglobin (13.60±1.73 vs. 12.92±1.63 mg/dL, p<0.001), slightly

| Table 1. Baseline clinical characteristics |
|-------------------------------------------|
| Overall (n=434) | Pattern A (n=327) | Pattern B (n=107) | p       |
|-----------------|-------------------|-------------------|---------|
| Age, years      | 64.3±9.7          | 64.5±9.5          | 63.7±10.4 | 0.475 |
| Male, n (%)     | 306 (70.5)        | 233 (71.3)        | 73 (68.2) | 0.544 |
| BMI (kg/m²)     | 25.7±9.2          | 25.7±10.5         | 25.7±2.6 | 0.993 |
| Acute coronary syndrome (%) | 218 (50.2) | 169 (51.7) | 49 (45.8) | 0.317 |
| Hypertension (%) | 286 (65.9)       | 212 (64.8)       | 74 (68.2) | 0.481 |
| Diabetes mellitus (%) | 150 (34.6) | 94 (28.7) | 34 (31.8) | 0.244 |
| Current smoker (%) | 90 (22.3)        | 66 (21.8)        | 24 (24.0) | 0.768 |
| Serum creatinine (mg/dL) | 1.13±0.47       | 1.13±0.49         | 1.11±0.40 | 0.747 |
| Hemoglobin (g/dL) | 13.35±1.72       | 13.36±1.74       | 13.33±1.68 | 0.889 |
| HbA1c (%)       | 6.78±1.27         | 6.71±1.16         | 6.97±1.53 | 0.196 |
| CRP (mg/dL)     | 0.62±2.14         | 0.48±1.00         | 0.65±1.50 | 0.199 |
| Medication use before admission (%) |             |                   |         |
| Aspirin         | 283 (65.2)        | 212 (64.8)        | 71 (66.4) | 0.816 |
| Clopidogrel     | 184 (42.4)        | 139 (42.5)        | 45 (42.1) | 1.000 |
| Statin          | 189 (43.5)        | 153 (46.8)        | 36 (33.6) | 0.019 |
| Total cholesterol (mg/dL) | 151.80±36.20     | 146.13±34.71      | 169.10±35.31 | <0.001 |
| Triglyceride (mg/dL) | 140.08±76.81     | 142.47±77.72      | 132.36±73.68 | 0.279 |
| LDL-C (mg/dL)   | 91.38±33.37       | 92.42±32.48       | 88.03±36.08 | 0.280 |
| HDL-C (mg/dL)   | 34.57±9.68        | 35.69±10.06       | 31.15±7.47 | <0.001 |
| Mean LDL particle size (nm) | 26.74±0.56        | 26.98±0.25        | 26.00±0.61 | <0.001 |
| Sd-LDL fraction (%) | 10.87±13.36      | 4.89±4.95         | 29.15±14.37 | <0.001 |
| ARU             | 439.5±69.9        | 441.3±71.9        | 434.1±63.5 | 0.351 |
| HAPR (%)        | 147 (34)          | 117 (36.0)        | 30 (28.0) | 0.158 |
| PRU             | 239.7±85.7        | 237.9±87.3        | 244.9±80.7 | 0.465 |
| HCPR (%)        | 181 (41.7)        | 137 (41.9)        | 181 (41.7) | 0.911 |

Data are median±SD or number (%). BMI: body mass index, CRP: C-reactive protein, LDL-C: low density lipoprotein-cholesterol, HDL-C: high density lipoprotein-cholesterol, ARU: aspirin reaction units, HAPR: high on-aspirin platelet reactivity, PRU: P2Y12 reaction units, HCPR: high on-clopidogrel platelet reactivity, Sd-LDL: small dense low density lipoprotein-cholesterol.
Table 2. Comparison between HAPR and non-HAPR patients

| Predictors                  | Non-HAPR (n=286) | HAPR (n=148) | p    |
|----------------------------|------------------|--------------|------|
| Age (years)                | 63.5±9.3         | 65.8±10.5    | 0.023|
| Male sex (%)               | 202 (70.9)       | 104 (70.7)   | 1.000|
| BMI (kg/m²)                | 26.27±11.23      | 24.72±3.30   | 0.112|
| Acute coronary syndrome (%)| 133 (46.7)       | 83 (56.5)    | 0.067|
| Hypertension (%)           | 184 (64.6)       | 100 (68.0)   | 0.521|
| Diabetes mellitus (%)      | 91 (31.9)        | 59 (40.1)    | 0.109|
| Current smoker (%)         | 56 (21.7)        | 34 (23.8)    | 0.834|
| Aspirin medication before admission (%) | 195 (68.1) | 87 (59.2) | 0.071|
| Serum creatinine (mg/dL)   | 1.09±0.30        | 1.20±0.68    | 0.065|
| Hemoglobin (g/dL)          | 13.60±1.73       | 12.92±1.63   | <0.001|
| Total cholesterol (mg/dL)  | 152.9±35.6       | 150.0±37.4   | 0.431|
| TG (mg/dL)                 | 137.9±76.4       | 144.6±78.3   | 0.342|
| HDL-C (mg/dL)              | 34.0±9.0         | 35.8±10.8    | 0.064|
| LDL-C (mg/dL)              | 91.7±34.1        | 91.0±32.1    | 0.835|
| Pattern B (%)              | 77 (27.0)        | 30 (20.4)    | 0.158|
| Mean LDL particle diameter (nm) | 26.7±0.6  | 26.8±0.5    | 0.078|
| Sd-LDL fraction (%)        | 11.4±0.1         | 10.0±0.1     | 0.285|

Data are median±SD or number (%). HAPR: high on-Aspirin platelet reactivity, BMI: body mass index, TG: triglyceride, HDL-C: high density lipoprotein-cholesterol, LDL-C: low density lipoprotein-cholesterol, Sd-LDL: small dense low density lipoprotein-cholesterol.

Higher serum creatinine (1.09±0.30 vs. 1.20±0.68 mg/dL, p=0.065) and HbA1c (6.67±1.12 vs. 7.00±1.50%, p=0.065). The differences in mean LDL particle diameter between the 2 groups were not statistically significant (26.70±0.57 vs. 26.80±0.55 nm in non-HAPR vs. HAPR group, p=0.078). Even after adjustment for various differences, low serum hemoglobin (odds ratio [OR] 1.808, 95% confidence interval [CI] 1.027-3.184, p=0.040) was a significant predictor of HAPR, while pattern B was not (OR 0.722, 95% CI 0.431-1.209, p=0.216) (Table 3).

Clinical characteristics of patients with high on-clopidogrel platelet reactivity

A total of 181 patients were identified as having HCPR (Table 4). Patients in the HCPR group were also older (62.87±10.04 vs. 66.35±8.94 years, p<0.001), more likely to be diabetic (30.4% vs. 40.3%, p=0.04), hypertensive (61.7% vs. 71.8%, p=0.03), and less likely to be males (80.6% vs. 56.4%, p<0.001), or smokers (26.8% vs. 16.1%, p=0.001). Mean hemoglobin was significantly lower in the HCPR group (13.80±1.73 vs. 12.74±1.51 mg/dL, p<0.001). There were no differences in mean LDL particle diameters between the 2 groups (26.7±0.6 vs. 26.8±0.5 nm, p=0.857) and on multivariate analysis, pattern B was not a predictor of HCPR (OR 0.858, 95% CI 0.513-1.435, p=0.559). Low serum hemoglobin (OR 2.511, 95% CI 1.403-4.493, p=0.002) was a strong predictor of HCPR, while smoking showed a mild trend toward being protective against HCPR (OR 0.626, 95% CI 0.377-1.038, p=0.070) (Table 5).
Thus, we analyzed whether LDL particle size was associated with OPR. Several studies have addressed the relationship between LDL particle size and OPR.

Recently, we reported that this phenomenon was dependent on cytochrome P450-1A2 status, suggesting that the cytochrome P450 system may be important in patients with coronary artery disease and inter-individual differences in response to aspirin and clopidogrel have been previously reported. To the best of our knowledge, no previous study has addressed the relationship between LDL particle size and OPR.

Thus, we analyzed whether LDL particle size was associated with both response to aspirin and clopidogrel in those with coronary artery disease. The major finding of this study was that LDL particle size was not significantly associated with OPR and was not an independent predictor of HCPR.

Theoretically, there are various pathways by which sd-LDL could possibly stimulate platelet reactivity. It may promote the thromboxane synthesis and further influence platelet aggregation. In addition, sd-LDL particles are more susceptible to oxidation than large LDL and oxidized LDL stimulates platelet function more effectively by diminishing nitric oxide (NO) synthase expression, blocking CD36 and scavenger receptor A. Thus, pattern B could be expected to enhance OPR. However, in the present study, there was no significant association between LDL particle size and platelet reactivity in vivo.

Besides the obvious conclusion that LDL particle size has no effect on platelet function, there may be other possible explanations for our findings. First, several pathways are involved in platelet function homeostasis, including thromboxane, ADP, thrombin, and NO. Although sd-LDL could promote thromboxane synthesis, this may not be enough to significantly alter platelet reactivity. Second, the number of patients analyzed in the study was modest at best, and therefore, the number of patients in the present study may not have been enough to confirm the small effect of sd-LDL on platelet function. Third, since we measured platelet function in patients on dual anti-platelet therapy, the effects of sd-LDL on platelet function could have been attenuated. We could at least confirm that the effect of sd-LDL did not significantly alter response to clopidogrel or aspirin. Further studies in a larger patient population who are naive for anti-platelet agents using various platelet function assays will be required to confirm the true effect of sd-LDL on platelet function.

In the present analysis, lower serum hemoglobin was a strong predictor of both HAPR and HCPR. Previous studies suggested similar results. Lee et al. and Cecchi et al. reported that lower hematocrit was associated with HAPR and HCPR. Decreased erythrocyte mass could be associated with a low availability of NO, which inhibits platelet aggregation by increase of intracellular cyclic guanosine monophosphate levels in platelets. Also, erythrocytes were able to release ADP, which enhances NO release by platelets.

Cigarette smoking showed a mild trend toward being protective against HCPR. Many studies already reported enhanced clopidogrel response in smokers, so called "smokers’ paradox". We recently reported that this phenomenon was dependent on cytochrome P450-1A2 status, suggesting that the cytochrome P450 system may be involved in the mechanism of smokers’ paradox.

In this study, mean LDL particle size of the patients was 26.74±0.56 nm and 25% of patients showed pattern B lipid profile. In the study of Kwon et al. of Korean population underwent coronary an-

| Table 4. Comparison between HCPR and non-HCPR patients |
|--------------------------------------------------------|
| Prediction                                             | Non-HCPR (n=253) | HCPR (n=181) | p   |
| Age (years)                                            | 62.87±10.04      | 66.35±9.94  | <0.001 |
| Male sex (%)                                           | 204 (80.6)       | 102 (56.4) | <0.001 |
| BMI (kg/m²)                                            | 25.42±8.80       | 26.13±9.77 | 0.449 |
| Acute coronary syndrome (%)                            | 126 (49.8)       | 92 (50.8)  | 0.846 |
| Hypertension (%)                                       | 156 (61.7)       | 130 (71.8) | 0.031 |
| Diabetes mellitus (%)                                  | 77 (30.4)        | 73 (40.3)  | 0.040 |
| Current smoker (%)                                     | 63 (26.8)        | 27 (16.1)  | <0.001 |
| Clopidogrel medication before admission (%)           | 105 (41.5)       | 79 (43.6)  | 0.684 |
| Serum creatinine (mg/dL)                               | 1.10±0.34        | 1.16±0.61  | 0.212 |
| Hemoglobin (g/dL)                                      | 13.80±1.73       | 12.74±1.51 | <0.001 |
| Total cholesterol (mg/dL)                              | 158.76±33.56     | 156.04±39.30 | 0.044 |
| TG (mg/dL)                                             | 136.54±62.13     | 145.15±93.92 | 0.318 |
| HDL-C (mg/dL)                                          | 34.06±9.43       | 35.29±10.00 | 0.194 |
| LDL-C (mg/dL)                                          | 93.70±33.60      | 88.07±32.88 | 0.108 |
| Pattern B (%)                                          | 63 (26.8)        | 44 (24.3)  | 0.911 |
| Mean LDL particle diameter (nm)                        | 26.74±10.59      | 26.75±10.52 | 0.857 |
| Sd-LDL fraction (%)                                    | 10.8±0.1         | 11.0±0.1   | 0.884 |

Data are median±SD or number (%). HCPR: high on-clopidogrel platelet reactivity. BMI: body mass index. TG: triglyceride. HDL-C: high density lipoprotein-cholesterol. LDL-C: low density lipoprotein-cholesterol. Sd-LDL: small dense low density lipoprotein-cholesterol.

| Table 5. Predictors of HCPR: multivariate logistic regression analysis |
|---------------------------------------------------------------|
| Predictors                          | Odds ratio (95% CI) | p   |
| Acute coronary syndrome             | 0.892 (0.575–1.385) | 0.611 |
| Current smoker                      | 0.626 (0.377–1.038) | 0.070 |
| Clopidogrel use before admission    | 1.127 (0.720–1.763) | 0.602 |
| Low hemoglobin [<12 g/dL]           | 2.511 (1.403–4.493) | 0.002 |
| Pattern B                           | 0.858 (0.513–1.435) | 0.559 |

The multivariate model was constructed using logistic regression. Input covariates were age, gender, body mass index, diagnosis of acute coronary syndrome, hypertension, diabetes mellitus, smoking status, serum creatinine, serum hemoglobin, pattern B, medication before admission (aspirin, clopidogrel, statins). CI: confidence interval. HCPR: high on-clopidogrel platelet reactivity.

Discussion

Appropriate antiplatelet response to anti-platelet therapy is important in patients with coronary artery disease and inter-individu-
LDL Particle Size and On-Treatment Platelet Reactivity

556

Korean Circ J 2012;42:551-560

LDL Particle Size and On-Treatment Platelet Reactivity

1. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay; a 12-month follow-up. Circulation 2009;119:237–42.
2. Breet NJ, van Werkum JW, Bouman HJ, et al. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart 2011;97:983–90.
3. Kim JY, Yoon J. Aspirin and clopidogrel resistance in drug eluting stent era. Korean Circ J 2007;37:135–47.
4. Ip S, Lichtenstein AH, Chung M, Lau J, Baik EM. Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes. Ann Intern Med 2009;150:474–84.
5. El Harachaoui K, van der Steeg WA, Stroes ES, et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: The EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007;49:547–53.
6. Koba S, Yokota Y, Hirano T, et al. Small LDL-cholesterol is superior to LDL-cholesterol for determining severe coronary atherosclerosis. J Atheroscler Thromb 2008;15:250–60.
7. Rizzo M, Berneis K, Corrado E, Novo S. The significance of low-density lipoproteins size in vascular diseases. Int Angiol 2006;25:4–9.
8. Boren J, Gustafsson M, Skålen K, Flood C, Innerarity TL. Role of extra-cellular retention of low density lipoproteins in atherosclerosis. Curr Opin Lipidol 2000;11:451–6.
9. Hurt-Camejo E, Camejo G, Sartipy P. Phospholipase A2 and small, dense low-density lipoprotein. Curr Opin Lipidol 2000;11:465–71.
10. Weisser B, Locher R, de Graaf J, Moser R, Sachinidis A, Vetter W. Low density lipoprotein subfractions increase thromboxane formation in endothelial cells. Biochem Biophys Res Commun 1993;192:1245–50.
11. Hoefner DM, Hodel SD, O’Brien JF, et al. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem 2001;47:266–74.
12. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 1982;23:97–104.
13. Kazumi T, Kawaguchi A, Hozumi T, et al. Low density lipoprotein particle diameter in young, nonobese, normolipidemic Japanese men. Atherosclerosis 1999;142:113–9.
14. Yoon Y, Song J, Park HD, Park KU, Kim JQ. Significance of small dense low-density lipoprotein as coronary risk factor in diabetic and nondiabetic Korean populations. Clin Chem Lab Med 2005;43:431–7.
15. Kwon SW, Yoon SJ, Kang TS, et al. Significance of small dense low-density lipoprotein as a risk factor for coronary artery disease and acute coronary syndrome. Yonsei Med J 2006;47:405–14.
16. Van Werkum JW, Harmans ME, Eisenberg EH, Bouman HJ, ten Berg JM, Hackeng CM. The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence. Platelets 2008;19:479–88.
17. Paniccia R, Antonucci E, Gori AM, et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007;5:1839–47.
18. De Graaf J, Hak-Lemmers HL, Hectors MP, Demacker PN, Hendriks JC, Stalenhoph AF. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb Vasc Biol 1999;19:298–306.
19. Chen JY, Mehta P, Mehta JL. Oxidized LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets: relevance of the effect of oxidized LDL on platelet function. Circulation 1996;93:1740–6.
20. Wang JS, Lin CC, Chen JK, Wong MK. Role of chronic exercise in decreasing oxidized LDL-potentiated platelet activation by enhancing platelet-derived NO release and bioactivity in rats. Life Sci 2000;66:1937–48.
21. Collot-Teixeira S, De Lorenzo F, McGregor JL. Scavenger receptor A and CD36 are implicated in mediating platelet activation induced by oxidized low- density lipoproteins. *Arterioscler Thromb Vasc Biol* 2007; 27:2491-2.

22. Lee PY, Chen WH, Ng W, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. *Am J Med* 2005;118: 723-7.

23. Cecchi E, Marcucci R, Paniccia R, et al. Effect of blood hematocrit and erythrocyte deformability on adenosine 5'-diphosphate platelet reactivity in patients with acute coronary syndromes on dual antiplatelet therapy. *Am J Cardiol* 2009;104:764-8.

24. Kleinbongard P, Schulz R, Rassaf T, et al. Red blood cells express a functional endothelial nitric oxide synthase. *Blood* 2006;107:2943-51.

25. Carroll JS, Ku CJ, Karunaratne W, Spence DM. Red blood cell stimulation of platelet nitric oxide production indicated by quantitative monitoring of the communication between cells in the bloodstream. *Anal Chem* 2007;79:5133-8.

26. Park KW, Park JJ, Jeon KH, et al. Enhanced clopidogrel responsiveness in smokers: smokers’ paradox is dependent on cytochrome P450 CY-P1A2 status. *Arterioscler Thromb Vasc Biol* 2011;31:665-71.

27. Rosenson RS. Myocardial injury: the acute phase response and lipoprotein metabolism. *J Am Coll Cardiol* 1993;22:933-40.

28. Barth JH, Jackson BM, Farrin AJ, et al. Change in serum lipids after acute coronary syndromes: secondary analysis of SPACE ROCKET study data and a comparative literature review. *Clin Chem* 2010;56:1592-8.